Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
11 August 2000Website:
http://cgen.comNext earnings report:
12 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:47:21 GMTDividend
Analysts recommendations
Institutional Ownership
CGEN Latest News
HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open.
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company Solid balance sheet with cash runway expected to fund operations into 2027 HOLON, Israel , Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 1(current)
What type of business is Compugen?
Compugen Ltd. is an Israeli company specializing in therapeutic discoveries and developments. It was registered in Israel in 1993. The company's main focus is on discovering new drugs and developing therapeutic agents in the field of cancer immunotherapy. The innovative immuno-oncology program consists of three clinical-stage programs targeting immune checkpoints: COM701, BAY 1905254, and COM902. COM701 is a first-in-class antibody for the treatment of solid tumors, being clinically developed in collaboration with BMS (Bristol-Myers Squibb). BAY 1905254 has demonstrated anti-tumor activity as a monotherapy, and it also has additional anti-tumor activity in combination with other cancer therapy approaches, indicating the possibility of multiple combined uses in cancer immunotherapy. COM902 is a therapeutic antibody being developed for patients with advanced malignant neoplasms.
What sector is Compugen in?
Compugen is in the Healthcare sector
What industry is Compugen in?
Compugen is in the Biotechnology industry
What country is Compugen from?
Compugen is headquartered in Israel
When did Compugen go public?
Compugen initial public offering (IPO) was on 11 August 2000
What is Compugen website?
https://cgen.com
Is Compugen in the S&P 500?
No, Compugen is not included in the S&P 500 index
Is Compugen in the NASDAQ 100?
No, Compugen is not included in the NASDAQ 100 index
Is Compugen in the Dow Jones?
No, Compugen is not included in the Dow Jones index
When was Compugen the previous earnings report?
No data
When does Compugen earnings report?
The next expected earnings date for Compugen is 12 November 2024